CAMBRIDGE, Mass., Dec. 17, 2015 /PRNewswire/ -- Blueprint
Medicines (NASDAQ: BPMC), a leader in discovering and developing
highly selective kinase medicines for patients with genomically
defined diseases, today announced that it has been added to the
NASDAQ Biotechnology Index® (NASDAQ: NBI). The annual
re-constitution of the NASDAQ Biotechnology Index will become
effective upon market open on Monday,
December 21, 2015.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of securities listed on The NASDAQ Stock
Market ® (NASDAQ®) that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB). The NASDAQ Biotechnology Index is calculated under a
modified capitalization-weighted methodology and ranked on an
annual basis. All securities in the NASDAQ Biotechnology Index are
listed on the NASDAQ Global Market or the NASDAQ Global Select
Market and meet certain eligibility requirements. For more
information about the NASDAQ Biotechnology Index, including
eligibility criteria, visit www.nasdaq.com.
The NASDAQ Biotechnology Index is the basis for the iShares
NASDAQ Biotechnology Index(SM) Fund (NASDAQ: IBB), which
seeks investment results that correspond generally to the price and
yield performance, before fees and expenses, of the NASDAQ
Biotechnology Index. In addition, options based on the iShares
NASDAQ Biotechnology Index Fund trade on various exchanges.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of highly
selective and potent kinase medicines to improve the lives of
patients with genomically defined diseases. The Company's approach
is rooted in a deep understanding of the genetic blueprint of
cancer and other diseases driven by the abnormal activation of
kinases. Blueprint Medicines is advancing three programs in
clinical development for subsets of patients with gastrointestinal
stromal tumors, hepatocellular carcinoma and systemic mastocytosis,
as well as multiple programs in research and preclinical
development. For more information, please visit
www.blueprintmedicines.com.
Logo - http://photos.prnewswire.com/prnh/20150605/221118LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/blueprint-medicines-added-to-nasdaq-biotechnology-index-300194475.html
SOURCE Blueprint Medicines